IP Library › Granted Patent US 11,260,058
Granted Patent B2
US 11,260,058 · App. 16/497,430 · Granted Mar 1, 2022

Compositions and method of treating cancer

Inventors: Richard L. Gallo (San Diego, CA); Teruaki Nakatsuji (San Diego, CA)
Assignee: The Regents of the University of California
A61K31/52A61K9/0014A61K9/06A61K35/741A61P31/00A61P35/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,058
App. No.
16/497,430
Granted
Mar 1, 2022
Kind
B2
Abstract

The disclosure provides for compounds of the general structure: and methods of using and compositions comprising the compounds for treating infections, cancer and neoplastic diseases and disorders.

Claims (17)

1. A method for inhibiting the growth, migration, proliferation and/or metastasis of a pre-cancer, cancer or neoplastic cell or inhibiting a pathogen, wherein the pre-cancer, cancer or neoplastic cell is selected from the group consisting of melanoma, squamous cell carcinoma, actinic keratosis, keratoacanthoma, and basal cell carcinoma, comprising contacting the cell or pathogen with an inhibiting effective amount of a composition comprising a compound of Formula I(a):

or a pharmaceutically acceptable salt or thereof, wherein,

N 1 —N 5 are nitrogen atoms;

X 1 -X 2 are carbon atoms;

the R groups attached by a dashed line are present, or are not present if the R group is connected to an atom that is bound to another atom by a double covalent bond;

the bond indicated by both a straight line and a dashed line indicate that the bond may be a single covalent bond or a double covalent bond;

the fused heterocyclic ring system comprises three double bonds with N 2 or N 3 forming a double bond and with X 1 , and with N 4 or N 5 forming a double bond with X 2 ;

R 1 is a hydroxyl; and

R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently a H, D, or optionally substituted (C 1 -C 3 )-alkyl.

2. The method of claim 1 , wherein the cancer cell is contacted in vivo.

3. The method of claim 1 , wherein the contacting is through topical administration.

4. The method of claim 1 , wherein the composition further comprises a chemotherapeutic agent.

5. The method of claim 1 , wherein the composition is formulated for topical administration.

6. The method of claim 1 , wherein the composition is formulated for systemic administration.

7. The method of claim 1 , wherein the composition comprises a commensal probiotic bacteria that produces the compound of Formula I(a), I(b) or II.

8. The method of claim 7 , wherein the commensal probiotic bacteria expresses 1 or more of the sequences set forth in SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, and/or 55.

9. The method of claim 7 , wherein the commensal probiotic bacteria comprises S. epidermidis strain MO34 and/or MO38.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2019
From: GALLO, RICHARD L.; NAKATSUJI, TERUAKI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 051382/0853 →
Continuity (3)
Provisional Application 62638058 · Mar 2, 2018
Provisional Application 62477370 · Mar 27, 2017
Related Publication 20200108073A1 · Apr 9, 2020
Cited By (1)
US 12,427,151